{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:10:09Z","timestamp":1781629809613,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder urothelial carcinoma (UC) represents a prevalent and clinically aggressive malignancy. For cisplatin-intolerant patients, there remains an urgent need to investigate alternative therapeutic regimens. This case report describes the application of combined immunotherapy and HER2-targeted antibody\u2013drug conjugate (ADC) therapy in a patient with gemcitabine plus cisplatin (GC regimen) intolerant bladder UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 66-year-old female patient was diagnosed with human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry 2+\/3+) bladder UC (T3N0M0). Initial gemcitabine-cisplatin chemotherapy was discontinued due to severe adverse effects. The patient subsequently received four cycles of tislelizumab, an anti-programmed cell death protein-1 monoclonal antibody and five cycles of disitamab vedotin, a HER2-targeted ADC, as neoadjuvant therapy. The treatment was well tolerated, with mild adverse events. Following treatment, the patient underwent laparoscopic radical cystectomy with ileal neobladder reconstruction. The pathological diagnosis revealed treatment-related changes consistent with pathological complete response (pCR), with no recurrence observed during the 9-month postoperative follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates that neoadjuvant immunotherapy combined with HER2-targeted ADC therapy achieved pCR with a favourable safety profile in a GC regimen-intolerant patient with HER2-positive bladder UC. This result supports the further evaluation of this approach in both clinical studies and real-world practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-026-02049-w","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:54:27Z","timestamp":1768013667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant immunotherapy combined with HER2-targeted antibody\u2013drug conjugate in bladder urothelial carcinoma: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhengmin","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"issue":"3","key":"2049_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2049_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","volume":"84","author":"I Jubber","year":"2023","unstructured":"Jubber I, Ong S, Bukavina L, Black PC, Comp\u00e9rat E, Kamat AM, et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur Urol. 2023;84(2):176\u201390.","journal-title":"Eur Urol"},{"key":"2049_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103795","volume":"178","author":"V de Ruiz Porras","year":"2022","unstructured":"de Ruiz Porras V, Pardo JC, Etxaniz O, Font A. Neoadjuvant therapy for muscle-invasive bladder cancer: current clinical scenario, future perspectives, and unsolved questions. Crit Rev Oncol Hematol. 2022;178:103795.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2049_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.912699","volume":"12","author":"G Roviello","year":"2022","unstructured":"Roviello G, Catalano M, Santi R, Santoni M, Galli IC, Amorosi A, et al. Neoadjuvant treatment in muscle-invasive bladder cancer: from the beginning to the latest developments. Front Oncol. 2022;12:912699.","journal-title":"Front Oncol"},{"issue":"9","key":"2049_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/14712598.2023.2238607","volume":"23","author":"P Ghatalia","year":"2023","unstructured":"Ghatalia P, Kaur J, Sonpavde G. Muscle invasive bladder cancer: where is the field headed? Expert Opin Biol Ther. 2023;23(9):913\u201327.","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"2049_CR6","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","volume":"26","author":"J Gao","year":"2020","unstructured":"Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020;26(12):1845\u201351.","journal-title":"Nat Med"},{"issue":"1","key":"2049_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02796-6","volume":"16","author":"W He","year":"2025","unstructured":"He W, Xie J, Wang Z, Wang M, Chen Q, Zhang C, et al. Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancer. Discover Oncol. 2025;16(1):1197.","journal-title":"Discover Oncol"},{"issue":"2","key":"2049_CR8","first-page":"e79002","volume":"17","author":"KA Alqarni","year":"2025","unstructured":"Alqarni KA. Recent advances in immunotherapy for bladder cancer treatment. Cureus. 2025;17(2):e79002.","journal-title":"Cureus"},{"issue":"1","key":"2049_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.24.00340","volume":"43","author":"MD Galsky","year":"2025","unstructured":"Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274. J Clin Oncol. 2025;43(1):15\u201321.","journal-title":"J Clin Oncol"},{"key":"2049_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1233196","volume":"13","author":"F Wen","year":"2024","unstructured":"Wen F, Lin T, Zhang P, Shen Y. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib\/II study (HOPE-03). Front Oncol. 2024;13:1233196.","journal-title":"Front Oncol"},{"issue":"23","key":"2049_CR11","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","volume":"393","author":"X Sheng","year":"2025","unstructured":"Sheng X, Zeng G, Zhang C, Zhang Q, Bian J, Niu H, et al. Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer. N Engl J Med. 2025;393(23):2324\u201337.","journal-title":"N Engl J Med"},{"key":"2049_CR12","unstructured":"Vulsteke C et al. Perioperative enfortumab vedotin plus pembrolizumab improves survival outcomes in cisplatin-ineligible muscle-invasive bladder cancer. Presented at ESMO Congress 2025; 19 October, Berlin, Germany."},{"issue":"32","key":"2049_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039187","volume":"103","author":"L Li","year":"2024","unstructured":"Li L, Liu K, Ma X, Wu Y, Wang C, Wang Y. Primary exophytic urothelial carcinoma of the bladder: a case report. Medicine (Baltimore). 2024;103(32):e39187.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2049_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10238-025-01655-6","volume":"25","author":"Y Lv","year":"2025","unstructured":"Lv Y, Cui X, Li T, Liu C, Wang A, Wang T, et al. Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors. Clin Exp Med. 2025;25(1):139.","journal-title":"Clin Exp Med"},{"key":"2049_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1230395","volume":"14","author":"Y Wei","year":"2023","unstructured":"Wei Y, Zhang R, Yu C, Hong Z, Lin L, Li T, et al. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center\u2019s real-world study. Front Pharmacol. 2023;14:1230395.","journal-title":"Front Pharmacol"},{"key":"2049_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1549647","volume":"16","author":"C Zhang","year":"2025","unstructured":"Zhang C, Yu Y, Zhou Q, Ouyang J, Zhang Z. Disitamab vedotin vs. gemcitabine-cisplatin regimen with immunotherapy: a comparative analysis of efficacy and safety in muscle-invasive bladder cancer. Front Immunol. 2025;16:1549647.","journal-title":"Front Immunol"},{"issue":"3","key":"2049_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","volume":"36","author":"L Zhou","year":"2025","unstructured":"Zhou L, Yang KW, Zhang S, Yan XQ, Li SM, Xu HY, et al. Disitamab Vedotin plus Toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study. Ann Oncol. 2025;36(3):331\u20139.","journal-title":"Ann Oncol"},{"issue":"3","key":"2049_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102085","volume":"22","author":"A Wang","year":"2024","unstructured":"Wang A, Chen M, Li D, Shi J, Tang W, Zhang Z, et al. Disitamab vedotin alone or in combination with immune checkpoint inhibitors in bladder-sparing treatment of muscle-invasive bladder cancer: a real-world study. Clin Genitourin Cancer. 2024;22(3):102085.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"2049_CR19","doi-asserted-by":"publisher","first-page":"e70033","DOI":"10.1002\/imt2.70033","volume":"4","author":"J Hu","year":"2025","unstructured":"Hu J, Yan L, Liu J, Chen M, Liu P, Deng D, et al. Efficacy and biomarker analysis of neoadjuvant disitamab Vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study. Imeta. 2025;4(3):e70033.","journal-title":"Imeta"},{"issue":"24","key":"2049_CR20","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","volume":"30","author":"E Hamilton","year":"2024","unstructured":"Hamilton E, Galsky MD, Ochsenreither S, Del Conte G, Mart\u00edn M, De Miguel M, et al. Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study. Clin Cancer Res. 2024;30(24):5548\u201358.","journal-title":"Clin Cancer Res"},{"key":"2049_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-025-01075-x","author":"D Raggi","year":"2025","unstructured":"Raggi D, Crupi E, Pederzoli F, Martini A, Briganti A, Alhalabi O, et al. HER2 and urothelial carcinoma: current Understanding and future directions. Nat Rev Urol. 2025. https:\/\/doi.org\/10.1038\/s41585-025-01075-x. Epub ahead of print.","journal-title":"Nat Rev Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02049-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:32:14Z","timestamp":1781627534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-026-02049-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2049"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02049-w","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our institution does not require ethical approval for reporting individual cases or case series.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report. We obtained comprehensive written informed consent from the patient, encompassing both participation in the study and publication of clinical details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}